Washington, DC — According to state and local economic development sources Alexion Pharmaceuticals plans to invest $914,400.00 to build out 3,712 square feet of new space in Washington. The company plans to occupy the new space at 1455 Pennsylvania Ave NW in Washington, on or about March 1, 2021. According to the company website Our mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do. We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).

To learn more about Alexion Pharmaceuticals, visit http://alexion.com/

Company Contact:
Ludwig Hantson, Chief Executive Officer
ludwig.hantson@alexion.com
https://www.linkedin.com/in/ludwighantson/
475-230-2596

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved